ATE477274T1 - Gegen clostridium difficile gerichtete antikörper - Google Patents

Gegen clostridium difficile gerichtete antikörper

Info

Publication number
ATE477274T1
ATE477274T1 AT04727315T AT04727315T ATE477274T1 AT E477274 T1 ATE477274 T1 AT E477274T1 AT 04727315 T AT04727315 T AT 04727315T AT 04727315 T AT04727315 T AT 04727315T AT E477274 T1 ATE477274 T1 AT E477274T1
Authority
AT
Austria
Prior art keywords
clostridium difficile
directed against
antibodies directed
against clostridium
seq
Prior art date
Application number
AT04727315T
Other languages
English (en)
Inventor
James Burnie
Ruth Matthews
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Application granted granted Critical
Publication of ATE477274T1 publication Critical patent/ATE477274T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04727315T 2003-04-17 2004-04-14 Gegen clostridium difficile gerichtete antikörper ATE477274T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0309126.1A GB0309126D0 (en) 2003-04-17 2003-04-17 Clostridium difficile focussed antibodies
PCT/GB2004/001619 WO2004094474A1 (en) 2003-04-17 2004-04-14 Clostridium difficile focussed antibodies

Publications (1)

Publication Number Publication Date
ATE477274T1 true ATE477274T1 (de) 2010-08-15

Family

ID=9957095

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04727315T ATE477274T1 (de) 2003-04-17 2004-04-14 Gegen clostridium difficile gerichtete antikörper

Country Status (8)

Country Link
US (1) US20070071763A1 (de)
EP (2) EP2261253A3 (de)
JP (1) JP2007527370A (de)
AT (1) ATE477274T1 (de)
CA (1) CA2522086A1 (de)
DE (1) DE602004028592D1 (de)
GB (1) GB0309126D0 (de)
WO (1) WO2004094474A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
EP1833510A4 (de) * 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva Oral verabreichbare und anti-toxin-antikörper und herstellungs- und anwendungsverfahren dafür
EP2088432A1 (de) * 2008-02-11 2009-08-12 MorphoSys AG Verfahren zur Identifikation eines Antikörpers oder eines Targets
EP2405940B1 (de) 2009-02-20 2021-08-04 Secretary of State for Health and Social Care Antikörper gegen clostridium difficile toxine
WO2010136598A1 (en) 2009-05-29 2010-12-02 Morphosys Ag A collection and methods for its use
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
HRP20181811T1 (hr) 2010-11-19 2018-12-28 Morphosys Ag Zbirka sljedova protutijela i njezina upotreba
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
NZ714516A (en) 2012-03-02 2017-06-30 Regeneron Pharma Human antibodies to clostridium difficile toxins
EP2921502A4 (de) * 2012-10-19 2016-09-28 Evec Inc Gegen toxin aus clostridium difficile oder antigenbindendem fragment spezifischer menschlicher antikörper
US10117933B2 (en) * 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
SG11201503719WA (en) * 2012-11-29 2015-06-29 Bayer Healthcare Llc MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC)
JP2021505637A (ja) * 2017-12-12 2021-02-18 マクロジェニクス，インコーポレーテッド 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
WO2022061292A2 (en) * 2020-09-21 2022-03-24 The Board Of Regents Of The University Of Texas System Therapeutic agents and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
DE3430339C1 (de) 1984-08-17 1986-02-20 Nixdorf Computer Ag, 4790 Paderborn Empfangsschaltung fuer ein bipolares Eingangssignal
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
JPH02501533A (ja) 1987-09-09 1990-05-31 セルテック　リミテッド ポリペプチド製造
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
NZ291659A (en) 1994-09-06 2001-04-27 Galagen Inc Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1024826B1 (de) 1997-10-20 2005-03-16 Acambis, Inc. Passive immunisierung gegen durch clostridium difficile verursachte krankheit
ES2241267T3 (es) * 1998-04-01 2005-10-16 Danisco A/S Exoamilasas no maltogenicas y su utilizacion en el retraso de la retrogradacion del almidon.
EP1097172A1 (de) * 1998-07-21 2001-05-09 Genmab A/S Anti-hepatitis c virus antikörper und verwendung davon
DE69901569T2 (de) * 1998-08-28 2002-12-19 Genentech, Inc. Humane antikörper gegen faktor ix/ixa
GB0008305D0 (en) 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections
US20030054009A1 (en) 2001-02-09 2003-03-20 Windle Henry J. Clostridium difficile vaccine
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology

Also Published As

Publication number Publication date
EP2261253A2 (de) 2010-12-15
WO2004094474A1 (en) 2004-11-04
GB0309126D0 (en) 2003-05-28
JP2007527370A (ja) 2007-09-27
CA2522086A1 (en) 2004-11-04
EP1613655A1 (de) 2006-01-11
DE602004028592D1 (de) 2010-09-23
EP1613655B1 (de) 2010-08-11
EP2261253A3 (de) 2011-06-01
US20070071763A1 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
DE602004028592D1 (de) Gegen clostridium difficile gerichtete antikörper
NZ588457A (en) Humanized anti-factor d antibodies and uses thereof
DE60322188D1 (de) Zytokin (zcytor17-ligand)
IL267186B (en) Regulatory t-cell epitopes, their preparations and uses
DE60131456D1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
ATE554107T1 (de) Als therapeutika geeignete monovalente antikörperfragmente
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ626665A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
NZ590890A (en) Neutralizing anti-influenza a virus antibodies and uses thereof
NZ585622A (en) Hepatitis c virus antibodies
NZ603529A (en) Antibodies to human gdf8
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
ATE446972T1 (de) Il-1 bindende antikörper und fragmente davon
NZ598063A (en) Gram-positive bacteria specific binding compounds
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
BRPI0417992A (pt) método para purificar fsh
NZ547629A (en) Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
DK1545609T3 (da) Antistoffer rettet mod oxideret apolipoprotein B
ATE449177T1 (de) Staphylococcus epidermidis antigene
ATE414154T1 (de) Moraxella (branhamella) catarrhalis antigene
ATE421586T1 (de) Moraxella (branhamella) catarrhalis antigene
NZ603751A (en) Composition for treating disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties